Torrent Pharma Q3 Results Review - India, Latin America Drive Earnings: Motilal Oswal

Motilal Oswal Report

Torrent Pharmaceuticals Ltd. delivered an in-line operating performance in Q3 FY24. Healthy Ebitda growth of 18% YoY was driven by superior growth in domestic formulation and LatAm.

The lack of approvals and marginal price erosion in base business in the U.S. affected the overall performance to some extent.

We marginally lower our FY24 estimate by 3% to factor in lower other income. We maintain our estimates for FY25/FY26. We value Torrent Phram at 30 times 12 months forward earnings to arrive at a target price of Rs 2,540.

Torrent Pharma continues to build levers for its branded generics segment in DF/LATAM through a focused approach on existing brands, selective/differentiated product launches, and the addition of MRs to expand reach.

Further, it is also gearing up for launches in the U.S. generics segment from its Dahej site. Tender wins are improving its growth prospects in Germany as well.

Accordingly, we expect a 30% earnings compound annual growth rate over FY24-25. Having said this, the valuation largely factors in this upside in earnings. Retain 'Neutral' on the stock.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.